EUVIMEDEUVIMED entdecken
Crossref

Diagnostic value of a combined AMACR, P63, and ERG immunohistochemical panel in distinguishing benign from malignant prostate lesions

Gaurav Sharma, Shalini Sharma, Prachi Kumar, Rahul Bhargava, Himanshu Agrawal

International Journal of Health Sciences · 01.05.2026 · 20 · 163-171

DOI: 10.25259/ijhs_385_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Health Sciences, online erschienen am 01.05.2026. Verfasst von Gaurav Sharma und 4 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Diagnosing prostate cancer is difficult because its histological traits often overlap with those of benign conditions. Alpha-methylacyl-CoA racemase (AMACR), tumor protein 63 (P63), and erythroblast transformation-specific-related gene (ERG) are commonly utilized immunohistochemical markers. The triple-marker panel showed a marginal incremental diagnostic benefit over AMACR alone and may improve diagnostic confidence in selected difficult cases.

Methods

The specimens were immuno-stained with antibodies targeting AMACR, P63, and ERG. Sensitivity and specificity for AMACR, P63, and ERG were determined. Hematoxylin and eosin staining is the reference standard as it is a rapid, cost-effective diagnostic tool offering excellent morphological detail, allowing accurate identification of architectural and cellular features for diagnosis, grading, and prognosis.

Results

Among the evaluated specimens, 128 (66%) showed benign prostatic hyperplasia, while 66 (34%) showed prostatic adenocarcinoma on histopathological examination (HPE). Perineural invasion occurred in 32 (48.5%) of malignant cases. AMACR immunohistochemical expression was found in 54 (82%) of malignant cases and 24 (18.7%) of benign cases. P63 expression was present in 122 (95.3%) benign lesions. ERG expression was observed in 23 (34.8%) of malignant cases. The diagnostic accuracy of AMACR, P63, and ERG was 98.3%, 89.7%, and 86%, respectively. The triple-marker panel (AMACR + P63 + ERG) achieved 97% sensitivity, 99.2% specificity, and 98.5% diagnostic accuracy, indicating an incremental diagnostic gain in prostate biopsy specimens.

Conclusion

The triple-marker panel yielded a diagnostic accuracy rate of 98.5%, despite ERG’s comparatively lower sensitivity. The combined use of AMACR, P63, and ERG may be considered in selected diagnostically challenging cases.

Zitieren

APA

Sharma, G., Sharma, S., Kumar, P., Bhargava, R., & Agrawal, H. (2026). Diagnostic value of a combined AMACR, P63, and ERG immunohistochemical panel in distinguishing benign from malignant prostate lesions. International Journal of Health Sciences, 20, 163-171. https://doi.org/10.25259/ijhs_385_2025

Vancouver

Sharma G, Sharma S, Kumar P, Bhargava R, Agrawal H. Diagnostic value of a combined AMACR, P63, and ERG immunohistochemical panel in distinguishing benign from malignant prostate lesions. International Journal of Health Sciences. 2026;20:163-171. doi:10.25259/ijhs_385_2025

BibTeX
@article{Sharma2026,
  author = {Sharma, Gaurav and Sharma, Shalini and Kumar, Prachi and Bhargava, Rahul and Agrawal, Himanshu},
  title = {Diagnostic value of a combined AMACR, P63, and ERG immunohistochemical panel in distinguishing benign from malignant prostate lesions},
  journal = {International Journal of Health Sciences},
  year = {2026},
  volume = {20},
  pages = {163--171},
  doi = {10.25259/ijhs_385_2025}
}
Kostenlos starten →